MX378190B - Composiciones para el uso en el tratamiento de trastornos oculares que usan dipiridamol. - Google Patents

Composiciones para el uso en el tratamiento de trastornos oculares que usan dipiridamol.

Info

Publication number
MX378190B
MX378190B MX2015012716A MX2015012716A MX378190B MX 378190 B MX378190 B MX 378190B MX 2015012716 A MX2015012716 A MX 2015012716A MX 2015012716 A MX2015012716 A MX 2015012716A MX 378190 B MX378190 B MX 378190B
Authority
MX
Mexico
Prior art keywords
compositions
eye disorders
treatment
dipyridamole
topically
Prior art date
Application number
MX2015012716A
Other languages
English (en)
Other versions
MX2015012716A (es
Inventor
Moshe Rogosnitzky
Original Assignee
O D Ocular Discovery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by O D Ocular Discovery Ltd filed Critical O D Ocular Discovery Ltd
Publication of MX2015012716A publication Critical patent/MX2015012716A/es
Publication of MX378190B publication Critical patent/MX378190B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención describe composiciones para el uso en el tratamiento de trastornos oculares, las composiciones que incluyen una cantidad efectiva de un dipiridamol administrado tópicamente. Preferiblemente, el dipiridamol administrado tópicamente es formulado como una solución. Preferiblemente, el dipiridamol administrado tópicamente es al menos un agente seleccionado del grupo que consistente de: dipiridamol, y su sal farmacéuticamente aceptable. Preferiblemente, la cantidad efectiva corresponde a una concentración de por lo menos aproximadamente una molaridad de 10-5. Preferiblemente, la cantidad efectiva se basa en la administración de un tratamiento de al menos una vez cada dos días.
MX2015012716A 2013-03-12 2014-03-11 Composiciones para el uso en el tratamiento de trastornos oculares que usan dipiridamol. MX378190B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL225179A IL225179A (en) 2013-03-12 2013-03-12 Compounds for use in ocular disorders using dipyridamole
PCT/IB2014/059645 WO2014141079A1 (en) 2013-03-12 2014-03-11 Compositions for use in treating eye disorders using dipyridamole

Publications (2)

Publication Number Publication Date
MX2015012716A MX2015012716A (es) 2016-07-06
MX378190B true MX378190B (es) 2025-03-10

Family

ID=48916407

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015012716A MX378190B (es) 2013-03-12 2014-03-11 Composiciones para el uso en el tratamiento de trastornos oculares que usan dipiridamol.

Country Status (14)

Country Link
EP (1) EP2968328A4 (es)
JP (1) JP6820658B2 (es)
KR (2) KR20210010638A (es)
CN (1) CN105188702B (es)
AU (1) AU2014229371B2 (es)
BR (1) BR112015022084A2 (es)
CA (1) CA2905594A1 (es)
CL (1) CL2015002627A1 (es)
EA (1) EA035966B1 (es)
IL (1) IL225179A (es)
MX (1) MX378190B (es)
MY (1) MY182591A (es)
SG (2) SG11201507092QA (es)
WO (1) WO2014141079A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2975000A1 (en) * 2015-01-28 2016-08-04 Realinn Life Science Limited Compounds for enhancing ppar.gamma. expression and nuclear translocation and therapeutic use thereof
US20180092776A1 (en) 2016-09-30 2018-04-05 Sara Heikali Method and device for treating and managing diseased ocular tissue
WO2021001806A1 (en) 2019-07-04 2021-01-07 Ocular Discovery Ltd. Stable dipyridamole formulations with reduced impurities
WO2021001805A1 (en) 2019-07-04 2021-01-07 Ocular Discovery Ltd. Stable dipyridamole formulations and their methods of preparation
WO2024125322A1 (zh) * 2022-12-16 2024-06-20 智泽童康(广州)生物科技有限公司 防治过敏性和/或炎症性疾病的双嘧达莫及其制剂

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07258084A (ja) * 1994-03-17 1995-10-09 Rohto Pharmaceut Co Ltd ジピリダモールを必須成分とする眼圧降下剤
US5780450A (en) * 1995-11-21 1998-07-14 Alcon Laboratories, Inc. Use of adenosine uptake inhibitors for treating retinal or optic nerve head damage
US20060104968A1 (en) * 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
EP1956906A4 (en) * 2005-11-09 2009-12-30 Combinatorx Inc METHODS, COMPOSITIONS AND KITS FOR THE TREATMENT OF PATHOLOGIES
WO2010056710A1 (en) * 2008-11-11 2010-05-20 Biovista, Inc. Compositions and methods for treating eye diseases
EP2363126A1 (en) * 2010-03-04 2011-09-07 SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. Composition comprising as active ingredient L-carnitine in combination with hydroxykynurenine-O-beta-DL-glucoside, for the prevention and/or treatment of pathologies of the eye due to ultraviolet radiation

Also Published As

Publication number Publication date
CL2015002627A1 (es) 2016-03-11
MX2015012716A (es) 2016-07-06
EP2968328A1 (en) 2016-01-20
EP2968328A4 (en) 2016-11-23
SG11201507092QA (en) 2015-10-29
EA201591653A1 (ru) 2017-05-31
AU2014229371B2 (en) 2018-05-10
AU2014229371A1 (en) 2015-10-29
JP6820658B2 (ja) 2021-01-27
MY182591A (en) 2021-01-26
IL225179A0 (en) 2013-06-27
IL225179A (en) 2017-01-31
BR112015022084A2 (pt) 2017-07-18
SG10201706937UA (en) 2017-09-28
CN105188702A (zh) 2015-12-23
JP2016514123A (ja) 2016-05-19
KR20150126021A (ko) 2015-11-10
KR20210010638A (ko) 2021-01-27
CN105188702B (zh) 2019-03-26
EA035966B1 (ru) 2020-09-07
WO2014141079A1 (en) 2014-09-18
CA2905594A1 (en) 2014-09-18

Similar Documents

Publication Publication Date Title
MX391850B (es) Compuestos para usarse en el tratamiento o mejoramiento de la enfermedad de huntington
CO2017011851A2 (es) Compuestos novedosos
MX389242B (es) Compuestos para su uso en el tratamiento de trastornos neuromusculares
MX388380B (es) Composiciones para usarse en el incremento de los niveles de glóbulos rojos y el tratamiento de enfermedad de células falciformes.
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
PH12016500511A1 (en) Selective grp94 inhibitors and uses thereof
EA201890641A2 (ru) СТИМУЛЯТОРЫ sGC
MX390084B (es) Moduladores del receptor p2x3 y p2x2/3 de diaminopirimidina para usarse en el tratamiento de la tos.
ECSP16008797A (es) Derivados de heterobicicloaril como inhibidores rorc2 y métodos de uso de los mismos
EA201892726A1 (ru) Дейтерированный палбоциклиб
BR112015029495A2 (pt) compostos heterocíclicos como inibidores da via de sinalização hedgehog
CR20150390A (es) Inhibidores de la yodoproteina basada en 2,3-dihidroimidazol[1,2-c]pirimidin-5(1-h)-ona-asociada a la fosfolipasa a2 (lp-pla2)
DOP2015000170A (es) Compuestos químicos
MX385987B (es) Intensificadores de aceptabilidad para alimento para mascotas, método de preparación y usos de los mismos.
UY37442A (es) Derivados de fenilamina 4-sustituidos y su uso para proteger cultivos al combatir microorganismos fitopatogénicos indeseados
MX2016006975A (es) Compuestos, composicion farmaceutica y metodos para su uso en el tratamiento de enfermedades inflamatorias.
AR097143A1 (es) Composición alimenticia mineral para lamer para rumiantes y método para prepararla
MX378190B (es) Composiciones para el uso en el tratamiento de trastornos oculares que usan dipiridamol.
EA201591434A1 (ru) Способ обеспечения глазной нейропротекции
MX2013010308A (es) 2,4-pirimidindiaminas sustituidas para uso en lupus discoide.
MX2015009277A (es) Formas de dosificacion y usos terapauticos de l-4-cloro quinurenina.
DOP2016000251A (es) Inhibidores de las vías de señalización de wnt
MX2015013151A (es) Métodos de tratamiento de disquinesia y trastornos relacionados.
ECSP13012988A (es) Derivados de tienopirimidina (2,3-d) y su uso para tratar arritmia
CL2015002188A1 (es) Agentes analgésicos oculares tópicos